Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

Neuromyelitis optica (NMO) is a disabling autoimmune disease associated with an elevation of anti-aquaporin 4 (AQP4) autoantibodies. Here, we present a case with NMO who responded to monthly administration of the anti-IL-6 receptor antibody tocilizumab. The treatment rapidly reduced the elevated num...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Manabu, Aranami, Toshimasa, Matsuoka, Takako, Nakamura, Masakazu, Miyake, Sachiko, Yamamura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713263/
https://www.ncbi.nlm.nih.gov/pubmed/22782533
http://dx.doi.org/10.1007/s10165-012-0715-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713263/
https://www.ncbi.nlm.nih.gov/pubmed/22782533
http://dx.doi.org/10.1007/s10165-012-0715-9

Ejemplares similares